AZN and DSNKY Related Headlines
Go Back- ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
- DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
- ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Daiichi Sankyo initiates phase 3 lung cancer trial with biomarker selection
- TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
- Daiichi Sankyo starts phase 3 trial for ENHERTU in endometrial cancer
- DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
- ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
- DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
- ENHERTU plus pertuzumab approved for first-line HER2+ metastatic breast cancer
- ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Daiichi Sankyo begins phase 3 ovarian cancer trial for ENHERTU
- DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
- Daiichi Sankyo begins phase 3 trial of ENHERTU for lung cancer
- DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
- DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
- ENHERTU shows 67% response rate in breast cancer trial
- ENHERTU cuts breast cancer recurrence risk by 53% in post-surgery trial
- ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
- ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
- DATROWAY plus rilvegostomig shows tumor responses in urothelial cancer trial
- DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
- DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Im
- FDA accepts ENHERTU application for early-stage breast cancer treatment
- ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
- ENHERTU shows significant benefit in HER2-positive early breast cancer trial
- ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Ris
- ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors
- ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
- DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
AZN and DSNKY Related Press Releases
Go Back- ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
- DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
- ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
- DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
- ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
- DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
- ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
- DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
- DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
- ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
- ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
- DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
- DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Im
- ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
- ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Ris
- ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors
- ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
- DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
